13C metabolic flux analysis shows that resistin impairs the metabolic response to insulin in L6E9 myotubes

BMC Systems Biology

Marta Cascante⁴  Philippe Rouet¹  Antonio Zorzano²  Yves Durocher³  Annie Turkieh¹  Fatima Smih¹  Romain Harmancey¹  Josep J Centelles⁴  Vitaly A Selivanov⁴  Anibal Miranda⁴  Silvia Marin⁴  Shirley Guzmán⁴ 

[1] Université Toulouse III Paul-Sabatier, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Equipe n°7, Toulouse, France;Institute for Research in Biomedicine (IRB Barcelona) and CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Barcelona, Spain;Animal Cell Technology Group, Biotechnology Research Institute, National Research Council Canada, Montreal, QC, Canada;Institute of Biomedicine of Universitat de Barcelona (IBUB) and CSIC-Associated Unit, Barcelona, Spain

关键词: Tracer-based metabolomics;    Bioinformatics;    Fluxomics;    Glucose metabolism;    Insulin resistance;    Resistin;   

Others  :  1126947
DOI  :  10.1186/s12918-014-0109-z

 received in 2014-05-12, accepted in 2014-08-29,  发布年份 2014

【 摘 要 】

Background

It has been suggested that the adipokine resistin links obesity and insulin resistance, although how resistin acts on muscle metabolism is controversial. We aimed to quantitatively analyse the effects of resistin on the glucose metabolic flux profile and on insulin response in L6E9 myotubes at the metabolic level using a tracer-based metabolomic approach and our in-house developed software, Isodyn.

Results

Resistin significantly increased glucose uptake and glycolysis, altering pyruvate utilisation by the cell. In the presence of resistin, insulin only slightly increased glucose uptake and glycolysis, and did not alter the flux profile around pyruvate induced by resistin. Resistin prevented the increase in gene expression in pyruvate dehydrogenase-E1 and the sharp decrease in gene expression in cytosolic phosphoenolpyruvate carboxykinase-1 induced by insulin.

Conclusions

These data suggest that resistin impairs the metabolic activation of insulin. This impairment cannot be explained by the activity of a single enzyme, but instead due to reorganisation of the whole metabolic flux distribution.

【 授权许可】

   
2014 Guzmán et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Sorensen TI: The changing lifestyle in the world. Body weight and what else? Diabetes Care 2000, 23(Suppl 2):B1-B4.
• [2]Lavie CJ, Milani RV, Ventura HO: Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009, 53:1925-1932.
• [3]Wijnhoven TM, van Raaij JM, Spinelli A, Rito AI, Hovengen R, Kunesova M, Starc G, Rutter H, Sjoberg A, Petrauskiene A, O´Dwyer U, Petrova S, Farrugia SV, Wauters M, Yngve A, Rubana IM, Breda J: WHO European Childhood Obesity Surveillance Initiative 2008: weight, height and body mass index in 6–9-year-old children. Pediatr Obes 2013, 8:79-97.
• [4]Poyrazoglu S, Bas F, Darendeliler F: Metabolic syndrome in young people. Curr Opin Endocrinol Diabetes Obes 2014, 21:56-63.
• [5]Chen L, Magliano DJ, Zimmet PZ: The worldwide epidemiology of type 2 diabetes mellitus–present and future perspectives. Nat Rev Endocrinol 2012, 8:228-236.
• [6]Gauthier MS, Ruderman NB: Adipose tissue inflammation and insulin resistance: all obese humans are not created equal. Biochem J 2010, 430:e1-e4.
• [7]Lolmede K, Duffaut C, Zakaroff-Girard A, Bouloumie A: Immune cells in adipose tissue: key players in metabolic disorders. Diabetes Metabol 2011, 37:283-290.
• [8]Donath MY, Shoelson SE: Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011, 11:98-107.
• [9]Samaras K, Botelho NK, Chisholm DJ, Lord RV: Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity 2010, 18:884-889.
• [10]Cao H: Adipocytokines in obesity and metabolic disease. J Endocrinol 2014, 220:T47-T59.
• [11]Coelho M, Oliveira T, Fernandes R: Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci 2013, 9:191-200.
• [12]Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, Frantz GD, Tumas DB, Peale FV Jr, Shelton DL, Hébert CC: FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000, 19:4046-4055.
• [13]Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
• [14]Lazar MA: Resistin- and obesity-associated metabolic diseases. Horm Metab Res 2007, 39:710-716.
• [15]Schwartz DR, Lazar MA: Human resistin: found in translation from mouse to man. Trends Endocrinol Metab 2011, 22:259-265.
• [16]Qatanani M, Szwergold NR, Greaves DR, Ahima RS, Lazar MA: Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest 2009, 119:531-539.
• [17]Park HK, Ahima RS: Resistin in rodents and humans. Diabetes Metab J 2013, 37:404-414.
• [18]DeFronzo RA: Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988, 37:667-687.
• [19]Fan HQ, Gu N, Liu F, Fei L, Pan XQ, Guo M, Chen RH, Guo XR: Prolonged exposure to resistin inhibits glucose uptake in rat skeletal muscles. Acta Pharmacol Sin 2007, 28:410-416.
• [20]Jorgensen SB, Honeyman J, Oakhill JS, Fazakerley D, Stockli J, Kemp BE, Steinberg GR: Oligomeric resistin impairs insulin and AICAR-stimulated glucose uptake in mouse skeletal muscle by inhibiting GLUT4 translocation. Am J Physiol Endocrinol Metab 2009, 297:E57-E66.
• [21]Moon B, Kwan JJ, Duddy N, Sweeney G, Begum N: Resistin inhibits glucose uptake in L6 cells independently of changes in insulin signaling and GLUT4 translocation. Am J Physiol Endocrinol Metab 2003, 285:E106-E115.
• [22]Palanivel R, Maida A, Liu Y, Sweeney G: Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetologia 2006, 49:183-190.
• [23]Palanivel R, Sweeney G: Regulation of fatty acid uptake and metabolism in L6 skeletal muscle cells by resistin. FEBS Lett 2005, 579:5049-5054.
• [24]Satoh H, Nguyen MT, Miles PD, Imamura T, Usui I, Olefsky JM: Adenovirus-mediated chronic “hyper-resistinemia” leads to in vivo insulin resistance in normal rats. J Clin Invest 2004, 114:224-231.
• [25]Dettmer K, Hammock BD: Metabolomics–a new exciting field within the “omics” sciences. Environ Health Perspect 2004, 112:A396-A397.
• [26]Selivanov VA, Marin S, Lee PW, Cascante M: Software for dynamic analysis of tracer-based metabolomic data: estimation of metabolic fluxes and their statistical analysis. Bioinformatics 2006, 22:2806-2812.
• [27]DeFronzo RA: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 1997, 50:191-197.
• [28]Constantin-Teodosiu D: Regulation of muscle pyruvate dehydrogenase complex in insulin resistance: effects of exercise and dichloroacetate. Diabetes Metab J 2013, 37:301-314.
• [29]Huang B, Wu P, Bowker-Kinley MM, Harris RA: Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-alpha ligands, glucocorticoids, and insulin. Diabetes 2002, 51:276-283.
• [30]Crabtree B, Newsholme EA: The activities of phosphorylase, hexokinase, phosphofructokinase, lactate dehydrogenase and the glycerol 3-phosphate dehydrogenases in muscles from vertebrates and invertebrates. Biochem J 1972, 126:49-58.
• [31]Hakimi P, Yang J, Casadesus G, Massillon D, Tolentino-Silva F, Nye CK, Cabrera ME, Hagen DR, Utter CB, Baghdy Y, Johnson DH, Wilson DL, Kirwan JP, Kalhan SC, Hanson RW: Overexpression of the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) in skeletal muscle repatterns energy metabolism in the mouse. J Biol Chem 2007, 282:32844-32855.
• [32]Minet AD, Gaster M: Pyruvate carboxylase is expressed in human skeletal muscle. Biochem Biophys Res Commun 2010, 402:196-197.
• [33]Selivanov VA, Meshalkina LE, Solovjeva ON, Kuchel PW, Ramos-Montoya A, Kochetov GA, Lee PW, Cascante M: Rapid simulation and analysis of isotopomer distributions using constraints based on enzyme mechanisms: an example from HT29 cancer cells. Bioinformatics 2005, 21:3558-3564.
• [34]Selivanov VA, Puigjaner J, Sillero A, Centelles JJ, Ramos-Montoya A, Lee PW, Cascante M: An optimized algorithm for flux estimation from isotopomer distribution in glucose metabolites. Bioinformatics 2004, 20:3387-3397.
• [35]Selivanov VA, Vizan P, Mollinedo F, Fan TW, Lee PW, Cascante M: Edelfosine-induced metabolic changes in cancer cells that precede the overproduction of reactive oxygen species and apoptosis.BMC Syst Biol 2010, 4:135.
• [36]de Mas IM, Selivanov VA, Marin S, Roca J, Oresic M, Agius L, Cascante M: Compartmentation of glycogen metabolism revealed from 13C isotopologue distributions.BMC Syst Biol 2011, 5:175.
• [37]Rosen ED, Spiegelman BM: Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006, 444:847-853.
• [38]Suarez E, Bach D, Cadefau J, Palacin M, Zorzano A, Guma A: A novel role of neuregulin in skeletal muscle. Neuregulin stimulates glucose uptake, glucose transporter translocation, and transporter expression in muscle cells. J Biol Chem 2001, 276:18257-18264.
• [39]van Winden W, Verheijen P, Heijnen S: Possible pitfalls of flux calculations based on (13)C-labeling. Metab Eng 2001, 3:151-162.
• [40]Lee FN, Zhang L, Zheng D, Choi WS, Youn JH: Insulin suppresses PDK-4 expression in skeletal muscle independently of plasma FFA. Am J Physiol Endocrinol Metab 2004, 287:E69-E74.
• [41]Quinn PG, Yeagley D: Insulin regulation of PEPCK gene expression: a model for rapid and reversible modulation. Curr Drug Targets Immune Endocr Metabol Disord 2005, 5:423-437.
• [42]Cifani C, Durocher Y, Pathak A, Penicaud L, Smih F, Massi M, Rouet P, Polidori C: Possible common central pathway for resistin and insulin in regulating food intake. Acta Physiol 2009, 196:395-400.
• [43]Marin S, Lee WN, Bassilian S, Lim S, Boros LG, Centelles JJ, FernAndez-Novell JM, Guinovart JJ, Cascante M: Dynamic profiling of the glucose metabolic network in fasted rat hepatocytes using [1,2-13C2]glucose. Biochem J 2004, 381:287-294.
• [44]Vizan P, Sanchez-Tena S, Alcarraz-Vizan G, Soler M, Messeguer R, Pujol MD, Lee WN, Cascante M: Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets. Carcinogenesis 2009, 30:946-952.
• [45]Lee WN, Byerley LO, Bergner EA, Edmond J: Mass isotopomer analysis: theoretical and practical considerations. Biol Mass Spectrom 1991, 20:451-458.
• [46]Harmancey R, Senard JM, Rouet P, Pathak A, Smih F: Adrenomedullin inhibits adipogenesis under transcriptional control of insulin. Diabetes 2007, 56:553-563.
• [47]Schmittgen TD, Zakrajsek BA: Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. J Biochem Biophys Methods 2000, 46:69-81.
• [48]Aerts JL, Gonzales MI, Topalian SL: Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR. BioTechniques 2004, 36:84-86. 88, 90–81